Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Receivables (2016 - 2021)

Achieve Life Sciences (ACHV) has disclosed Receivables for 11 consecutive years, with $351000.0 as the latest value for Q3 2021.

  • Quarterly Receivables changed N/A to $351000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $351000.0 through Sep 2021, changed N/A year-over-year, with the annual reading at $8000.0 for FY2019, 14.29% up from the prior year.
  • Receivables for Q3 2021 was $351000.0 at Achieve Life Sciences, up from $8000.0 in the prior quarter.
  • The five-year high for Receivables was $351000.0 in Q3 2021, with the low at $7000.0 in Q1 2018.
  • Average Receivables over 4 years is $107900.0, with a median of $47500.0 recorded in 2017.
  • The sharpest move saw Receivables plummeted 98.24% in 2017, then increased 14.29% in 2019.
  • Achieve Life Sciences' Receivables stood at $9000.0 in 2017, then decreased by 22.22% to $7000.0 in 2018, then increased by 14.29% to $8000.0 in 2019, then soared by 4287.5% to $351000.0 in 2021.
  • Per Business Quant, the three most recent readings for ACHV's Receivables are $351000.0 (Q3 2021), $8000.0 (Q4 2019), and $7000.0 (Q4 2018).